** Shares of CSL CSL.AX fall as much as 5.5% to A$255.4, their lowest levels since November 21, 2023
** The biopharmaceutical co has reported half-year net profit of $2.01 billion, lower than analysts' forecast of $2.09 billion
** Co says earnings weighed down by falling immunisation rates in the U.S., its largest market
** About 1.2 million shares change hands, vs the 30-day average of 558,040
** Stock fell 1.8% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。